Corbion has entered into a \"stalking horse\" stock and asset purchase agreement with TerraVia Holdings, Inc. The execution of the stock and asset purchase agreement is subject to a sale process to be conducted under Section 363 of the U.S. Bankruptcy Code.
Corbion offered a cash purchase price of approximately $20 million, in accordance with the terms and conditions of the stock and asset purchase agreement. The transaction is subject to the receipt of any higher offers from other potential bidders in an auction process as part of the Section 363 sale. As TerraVia\'s operations are currently loss making, Corbion expects the total financial commitments to be in excess of the cash purchase price.
San Francisco-based TerraVia manufactures microalgae ingredients including Omega-3 for animal nutrition, as well as tailored oils, structured fats and proteins for food and biochemical applications. It operates an R&D center in San Francisco, and two manufacturing facilities: one wholly-owned in Peoria, Illinois and one in Brazil in a joint venture (50.1% owned by TerraVia) with Bunge. The acquisition of TerraVia\'s microalgae platform would extend Corbion\'s product portfolio into algae-based fatty acids and proteins, while leveraging Corbion\'s extensive fermentation and downstream processing capabilities.
TerraVia announced it filed a voluntary petition under Chapter 11 of the U.S. Bankruptcy Code on August 2, 2017. The stock and asset purchase agreement will constitute a primary bid for substantially all of the TerraVia assets in a sale process to be conducted under Section 363 of the U.S. Bankruptcy Code.
The auction process and final agreement will be subject to the approval of the United States Bankruptcy Court for the District of Delaware. In addition, completion of the transaction remains subject to customary closing conditions and regulatory approvals. The auction process and transaction closing are expected to conclude within 60 to 90 days.